Research programme - anti-ROR1 chimeric antigen receptor NK cell therapy - Oncternal Therapeutics
Alternative Names: Anti-ROR1 NK cell therapy; CAR-NK cell therapy against ROR1Latest Information Update: 26 Jun 2022
At a glance
- Originator Oncternal Therapeutics
- Developer Karolinska Institute; Oncternal Therapeutics
- Class Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer